13 November 2017
C4XD presents data on its lead addiction programme: Orexin-1 antagonist
Programme demonstrates potential application across a broad range of substance use disorders
13 November 2017 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, presented new pre-clinical data on its Orexin-1 antagonist programme at Neuroscience 2017 on 11th November 2017 in Washington, DC.
C4XD’s lead programme, Orexin-1, aims to treat addiction by targeting the “craving” process itself and, therefore, can be applied across a broad range of substance use disorders. Of particular note, C4XD announced new efficacy data of its lead compound, C4X_3256, in in vivo models of nicotine self-administration and cue-induced reinstatement. This supports the development of this compound as a therapy across two distinct areas of nicotine abuse; smoking cessation and relapse in smokers.
“This set of studies strengthens C4XD’s pre-clinical data package for our lead Orexin-1 antagonist programme. We strongly believe that the programme presents a compelling commercial case for partnership due to its broad applicability to substance use as well as related disorders, such as anxiety, post-traumatic stress disorder, and impulse control. This is supported by the high level of pre-clinical partnering interest received that have enabled us to enter late-stage commercial discussions.”
Clive DixChief Executive Officer of C4XD
Data presentation details:
Title: Efficacy of a novel selective oral Orexin 1 receptor antagonist in rat models of nicotine self-administration and reinstatement
Authors: C. Murray, G. A. Higgins, B. P. Martin, T. Nowak, J. C. Fox;
C4X Discovery, Manchester, United Kingdom; Intervivo Solutions Inc, Toronto, ON, Canada
To view the full abstract, please follow this link.
For further information, please contact:
C4X Discovery Holdings plc
Clive Dix, Chief Executive Officer 07801 865 803
Panmure Gordon (UK) Limited (NOMAD and Broker) 020 7886 2500
Freddy Crossley, Duncan Monteith (Corporate Finance)
Tom Salvesen (Corporate Broking)
Consilium Strategic Communications
Mary-Jane Elliott, Matthew Neal, Melissa Gardiner 0203 709 5700
About C4X Discovery
C4X Discovery aims to become the world’s most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company’s goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry.
C4X Discovery has a state-of-the-art suite of proprietary technologies across the drug discovery process. The company’s innovative DNA-based target identification platform (Taxonomy3®) utilises human genetic datasets to identify novel patient-specific targets leading to greater discovery productivity and increased probability of clinical success. This is complemented by C4XD’s novel drug design platform which comprises two innovative chemistry technologies, Conformetrix and Molplex, that combine 4D molecular shape analyses (based on experimental data) with best-in-class computational chemistry. This provides new and unprecedented insight into the behaviour of drug molecules, enabling the production of potent selective compounds faster and more cost effectively than the industry standard.
C4X Discovery is advancing its in-house pipeline in addiction, diabetes and inflammation with a number of new drug candidates identified and further progress made towards the clinic. In selecting new targets C4X Discovery will focus on the high-value disease areas of inflammation and neurodegeneration, and will continue to maximise value from opportunistic areas, for example, immuno-oncology, addiction, and diabetes.
The Company was founded as a spin-out from the University of Manchester. It has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4XD to reach multiple value inflexion points since IPO.